SCHEMBL1016146

SCHEMBL1016146

Cc1cc(S(=O)(=O)c2ccccc2)ccc1[C@@H]1CCN(S(C)(=O)=O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.44
ALDH1A1 P00352 7/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
THRB P10828 1/20 0.43
HTT P42858 1/20 0.43
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
TP53 P04637 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
GLRA3 O75311 1/20 0.39
GLRB P48167 1/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
DRD2 P14416 1/20 0.38
PDE4B Q07343 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012906 0.85 PDE4B (0.47) HTR6ALDH1A1LMNATSHRNPSR1
SCHEMBL1016147 0.81 HTR6 (0.40) HTR6ALDH1A1L3MBTL1MAPTTP53
SCHEMBL12954778 0.77 HTR6 (0.55) HTR6ALDH1A1
SCHEMBL1013368 0.76 HTR6 (0.43) HTR6ALDH1A1LMNATSHRNPSR1
SCHEMBL1012908 0.75 HTR6 (0.41) HTR6ALDH1A1L3MBTL1POLBTP53
SCHEMBL1012769 0.75 PDE4B (0.47) HTR6SMN1; SMN2DRD2PDE4B
SCHEMBL1012768 0.75 PDE4B (0.47) HTR6SMN1; SMN2DRD2PDE4B
SCHEMBL1013489 0.75 HTR6 (0.55) HTR6
SCHEMBL1015115 0.75 HTR6 (0.55) HTR6
SCHEMBL1013490 0.75 HTR6 (0.55) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081890-B1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS HOFFMANN LA ROCHE (CH) 2011-01-12 EP disclosed
EP-2081890-B1 ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS HOFFMANN LA ROCHE (CH) 2011-01-12 EP disclosed
US-7776910-B2 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC (US) 2010-08-17 US disclosed
US-7776910-B2 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC (US) 2010-08-17 US disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 US disclosed
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors ROCHE PALO ALTO LLC 2008-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167361-A1 Arylsulfonyl pyrrolidines as 5-HT6 inhibitors HTR6, HTR1B, HTR1F HTR6 1/4885ALDH1A1 619/4885SMN1; SMN2 2066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.